I don’t see a lot of similarity. One drug has an orphan designation and the other drug is for a large indication where there is already an approved therapy.
They both filed under the same parameters (missed primary but extended survival) and the DNDN data was a lot stronger than DORB's data... If you think DORB's case is unusual, and thus unpredictable, then for you DNDN's Provenge should have been a slam dunk approval...
you have a lot to learn if you think Provenge's data is stronger than orbec's
Market Data 
Markets 
AI
